Q2 Earnings Forecast for RLAY Issued By Leerink Partnrs

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Relay Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share. Leerink Partnrs also issued estimates for Relay Therapeutics’ Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.20) EPS and FY2027 earnings at ($2.64) EPS.

Several other research analysts also recently commented on the company. Leerink Partners cut their target price on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Relay Therapeutics in a research note on Tuesday, January 14th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price on shares of Relay Therapeutics in a report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Relay Therapeutics has an average rating of “Moderate Buy” and an average target price of $20.50.

Relay Therapeutics Stock Performance

RLAY stock opened at $4.01 on Monday. Relay Therapeutics has a 52-week low of $3.50 and a 52-week high of $11.16. The company has a market capitalization of $671.19 million, a P/E ratio of -1.54 and a beta of 1.61. The company has a fifty day moving average price of $4.50 and a 200-day moving average price of $5.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Relay Therapeutics by 160.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 6,500 shares of the company’s stock valued at $27,000 after acquiring an additional 4,000 shares in the last quarter. Cibc World Markets Corp acquired a new stake in Relay Therapeutics in the 4th quarter valued at $47,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Relay Therapeutics during the third quarter worth $63,000. Portland Investment Counsel Inc. acquired a new position in Relay Therapeutics during the third quarter worth $71,000. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Relay Therapeutics by 52.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,654 shares of the company’s stock valued at $73,000 after buying an additional 6,104 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Insider Transactions at Relay Therapeutics

In related news, insider Peter Rahmer sold 16,576 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $4.45, for a total transaction of $73,763.20. Following the transaction, the insider now directly owns 308,754 shares of the company’s stock, valued at $1,373,955.30. This represents a 5.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sanjiv Patel sold 100,000 shares of Relay Therapeutics stock in a transaction on Monday, December 16th. The shares were sold at an average price of $5.00, for a total transaction of $500,000.00. Following the completion of the sale, the chief executive officer now directly owns 574,548 shares of the company’s stock, valued at approximately $2,872,740. This trade represents a 14.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 354,646 shares of company stock valued at $1,672,757 in the last quarter. 4.32% of the stock is currently owned by company insiders.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.